Amarin Corporation plc (AMRN) said Monday it has been informed by the U.S. Food and Drug Administration that no advisory committee meeting will be scheduled in connection with the FDA's review of the New Drug Application seeking approval for the use AMR101 in the treatment of patients with very high triglycerides, the company's lead product candidate.
The FDA has previously assigned a Prescription Drug User Fee Act date of July 26, 2012 for completion of its review of the AMR101 NDA.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.